Cryo-Cell International Inc (CCEL) stock
CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30
$4.85−0.55 (-10.19%)
Close on Nov 13, 2026Market cap $39.10MP/E –Yield –
Cryo-Cell International r&d expenses
Research and development expenses are spending on new products and technology.
Cryo-Cell International's R&D Expenses for the twelve months ending Aug 31, 2026 was $303.95K, down 49.0% year over year. For fiscal 2025 it was $376.26K, down 69.7% from the year before. Over ten years it grew 23.4% a year on average. The highest annual figure on record is $1.24M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $376.26K | -69.7% |
| FY2024 | Nov 30, 2024 | $1.24M | +6.1% |
| FY2023 | Nov 30, 2023 | $1.17M | +204.4% |
| FY2022 | Nov 30, 2022 | $384.79K | +671.6% |
| FY2021 | Nov 30, 2021 | $49.87K | +109.1% |
| FY2020 | Nov 30, 2020 | $23.85K | -20.9% |
| FY2019 | Nov 30, 2019 | $30.15K | -67.2% |
| FY2018 | Nov 30, 2018 | $91.85K | +123.1% |
| FY2017 | Nov 30, 2017 | $41.17K | -22.5% |
| FY2016 | Nov 30, 2016 | $53.10K | +16.0% |
| FY2015 | Nov 30, 2015 | $45.78K | -28.9% |
| FY2014 | Nov 30, 2014 | $64.37K | +78.0% |
| FY2013 | Nov 30, 2013 | $36.17K | -67.0% |
| FY2012 | Nov 30, 2012 | $109.64K | -40.4% |
| FY2011 | Nov 30, 2011 | $184.05K | +38.4% |
| FY2010 | Nov 30, 2010 | $132.99K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $53.62K | -13.0% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $99.78K | -24.2% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $65.76K | -33.0% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | $84.78K | -72.2% |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $61.63K | -68.2% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $131.71K | -45.4% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $98.14K | -80.5% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | $304.63K | -31.4% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $193.93K | -43.6% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $241.09K | -20.9% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $502.89K | +537.9% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $443.81K | +480.9% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $344.13K | +328.7% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $304.68K | +276.6% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $78.83K | -46.5% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $76.40K | +151.0% |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $80.27K | +702.4% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $80.90K | +2399.1% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $147.22K | +2278.4% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | $30.44K | +331.1% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $10.00K | +701.6% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $3.24K | -67.0% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $6.19K | +8.2% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $7.06K | -58.1% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $1.25K | -48.9% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $9.82K | +98.1% |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $5.72K | -2.8% |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $16.86K | -37.4% |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $2.44K | -89.0% |
| Q2 FY2019CQ2 2019 | May 31, 2019 | $4.96K | -83.1% |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | $5.88K | -56.1% |
| Q4 FY2018CQ4 2018 | Nov 30, 2018 | $26.92K | +54.0% |
| Q3 FY2018CQ3 2018 | Aug 31, 2018 | $22.23K | +9738.1% |
| Q2 FY2018CQ2 2018 | May 31, 2018 | $29.28K | +231.3% |
| Q1 FY2018CQ1 2018 | Feb 28, 2018 | $13.41K | -8.3% |
| Q4 FY2017CQ4 2017 | Nov 30, 2017 | $17.48K | -6.2% |
| Q3 FY2017CQ3 2017 | Aug 31, 2017 | $226 | – |
| Q2 FY2017CQ2 2017 | May 31, 2017 | $8.84K | – |
| Q1 FY2017CQ1 2017 | Feb 28, 2017 | $14.62K | – |
| Q4 FY2016CQ4 2016 | Nov 30, 2016 | $18.65K | – |
See a number that looks wrong?